Skip to main content
Premium Trial:

Request an Annual Quote

Janney Downgrades Danaher to Neutral

NEW YORK (GenomeWeb) – Investment bank Janney today downgraded Danaher's shares to a Neutral rating from a previous Buy rating, but kept its fair value estimate for the company at $95 per share.

In a research note, analyst Paul Knight said that Danaher "has more work to do on optimizing its portfolio, and we expect smaller organic growth surprises than other peers." In particular, he noted Danaher's 2.5 percent organic growth in the first quarter, which Knight said was the lowest among large cap science peers, such as Thermo Fisher Scientific, Waters, and Agilent Technologies.

He further said that Danaher needs to build and to "prune" its portfolio. While the firm's acquisition of Cepheid late last year adds a "meaningful growth driver" in the diagnostics space, "we see holes" in other parts of the firm's life sciences business. Its analytical instruments business is focused on mass spectrometry, and Knight said, in order to compete with Agilent and Thermo Fisher, Danaher will need to add more instruments.

Meanwhile, its dental business has seen only 1 percent organic growth on average over the last nine quarters, and "[w]e see limited R&D and [sales, general, and administrative expense] synergies with the rest of the portfolio," Knight wrote. He added that a transaction similar to Danaher's spinoff of test, measurement, and industrial firm Fortive in 2016, "would allow Danaher to better focus on being a life science pure-play," and allow "for smaller acquisitions to have a more meaningful impact."

In afternoon trading on the Nasdaq, Danaher shares were down a fraction of 1 percent at $85.57. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.